Combination

PSI Group, a Long-Established Global Logistics Service Provider, Plans to List on Nasdaq Through Merger with AIB Acquisition Corporation

Retrieved on: 
Thursday, December 28, 2023
Yee, Atmosphere, Partnership, Partner, Business analyst, LLP, Acquisition, Hope, AIB, Combination, Security (finance), Cooley LLP, PSI, Financial adviser

PSI is one of the renowned air freight forwarding specialists in Hong Kong, providing global logistics and supply chain service to clients of various industries, including postal operators, e-Commerce merchants, senders and consignees.

Key Points: 
  • PSI is one of the renowned air freight forwarding specialists in Hong Kong, providing global logistics and supply chain service to clients of various industries, including postal operators, e-Commerce merchants, senders and consignees.
  • Founded in 1993, the company is headquartered in Hong Kong with a global network, operating through its subsidiaries, namely Profit Sail Int’l Express (H.K.)
  • The company is managed and run by a group of professionals with over 30 years of combined expertise in the logistics and air/ocean freight industries.
  • Cooley LLP is serving as U.S. legal advisor, and Ogier is serving as Cayman Islands legal advisor to PSI in connection with the Business Combination.

SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

Retrieved on: 
Wednesday, December 27, 2023
Patient, DCR, Immunotherapy, National Cancer Institute, Rated R, Neoplasm, Survival, RECIST, GPS, CD8, Male, Standard of care, Progression-free survival, Trial of the century, Nivolumab, WT1, MPM, SLS, Combination, OS, PFS, Female, Pharmaceutical industry

NEW YORK, Dec. 27, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel therapies for a broad range of cancer indications, today announced follow-up clinical/immune-response data from a Phase 1 investigator-sponsored clinical trial of its lead clinical candidate, galinpepimut-S (GPS), combined with the checkpoint inhibitor nivolumab (Opdivo®) in patients with refractory/relapsed malignant pleural mesothelioma (MPM).

Key Points: 
  • Nine out of ten patients (90%) had sufficient samples collected to be analyzed for GPS-specific immune response.
  • All enrolled patients had either received and progressed with or were refractory to frontline pemetrexed-based chemotherapy.
  • Additional analyses for the correlation of immune response and survival benefit were performed.
  • Among the nine evaluable patients, four patients had a CD4+ immune response (44.4%) and three patients had a CD8+ immune response (33.3%) to GPS.

SomaLogic Issues Letter to Stockholders Reiterating Recommendation for Value Maximizing Merger with Standard BioTools

Retrieved on: 
Thursday, December 21, 2023
SomaLogic, Proteomics, Motivation, Risk, Sale, Standard BioTools, Research, Mergers and acquisitions, NDA, Special, Combination, Shareholder, ALL, Standard, Holding company

BOULDER, Colo., Dec. 21, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc. (Nasdaq: SLGC) today issued an open letter to stockholders highlighting the value maximizing merger entered into with Standard BioTools (Nasdaq: LAB) on October 4, 2023. The Company also filed an investor presentation, which can be found on the investor page of SomaLogic’s website at https://investors.somalogic.com/static-files/daa110f7-0cc3-4eaf-ba78-e0c....

Key Points: 
  • On January 4, 2024, we are holding our Special Stockholder Meeting to vote on our proposed merger with Standard BioTools – a merger that we believe is in the best interests of all SomaLogic stockholders.
  • Thank you for your support,
    The Company urges all stockholders to vote “FOR” the value maximizing transaction on the SomaLogic proxy card today.
  • A special meeting of SomaLogic stockholders is scheduled to be held virtually in connection with the proposed merger on January 4, 2024, at 12 p.m.
  • The merger remains on track to close in the first quarter of 2024, subject to approval by SomaLogic and Standard BioTools stockholders and satisfaction of other customary closing conditions.

Jupiter Acquisition Corporation Announces Mutually Agreed Termination of Business Combination Agreement With Filament Health Corp., Cancellation of Special Meeting of Stockholders and Redemption of Public Shares

Retrieved on: 
Wednesday, December 20, 2023
Transfer, Charter, Tax, Business analyst, Class, Sound, Combination, IPO, Security (finance)

Hobe Sound, FL, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Jupiter Acquisition Corporation (NASDAQ:JAQC) (“Jupiter”) today announced the mutually agreed termination of the previously announced business combination agreement with Filament Health Corp. (the “Business Combination Agreement”).

Key Points: 
  • Hobe Sound, FL, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Jupiter Acquisition Corporation (NASDAQ:JAQC) (“Jupiter”) today announced the mutually agreed termination of the previously announced business combination agreement with Filament Health Corp. (the “Business Combination Agreement”).
  • The special meeting of stockholders of Jupiter scheduled to reconvene on Thursday, December 28, 2023, at 12:00 p.m. Eastern Time, at which stockholders of Jupiter were to be asked to vote to approve the Business Combination Agreement and the business combination contemplated thereby, among other related matters, has been cancelled.
  • The per-share redemption price for the public shares is expected to be approximately $10.34 (as finally determined, the “Redemption Amount”).
  • Beneficial owners of public shares held in “street name,” however, will not need to take any action in order to receive the Redemption Amount.

Broad Capital Acquisition Corp Confirms Funding to Extend Period to Consummate Initial Business Combination to January 13, 2024

Retrieved on: 
Monday, December 18, 2023
BRAC, Business analyst, Acquisition, Combination

Dallas, Texas, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Broad Capital Acquisition Corp. (the “Company”) (NASDAQ: BRAC, BRACR, BRACU), a special purpose acquisition company formed by Broad Capital LLC, today announced that on December 12, 2023 it caused to be deposited $150,000 (the “Extension Payment”) into the Company’s trust account for its public stockholders, representing $0.0332 per public share, allowing the Company to extend the period of time it has to consummate its initial business combination to January 13, 2024 (the “Monthly Extension”).

Key Points: 
  • Dallas, Texas, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Broad Capital Acquisition Corp. (the “Company”) (NASDAQ: BRAC, BRACR, BRACU), a special purpose acquisition company formed by Broad Capital LLC, today announced that on December 12, 2023 it caused to be deposited $150,000 (the “Extension Payment”) into the Company’s trust account for its public stockholders, representing $0.0332 per public share, allowing the Company to extend the period of time it has to consummate its initial business combination to January 13, 2024 (the “Monthly Extension”).
  • The Monthly Extension is the twelfth of the twelve monthly extensions permitted under the Company’s governing documents.
  • On January 18, 2023, the Company entered into a definitive Agreement and Plan of Merger and Business Combination Agreement (the “Business Combination Agreement”) with Openmarkets Group Pty Ltd, an Australian proprietary limited company (“OMG”), BMYG OMG Pty Ltd, an Australian proprietary limited company, and Broad Capital LLC, a Delaware limited liability company, solely in its capacity as the Company’s sponsor, pursuant to which the Company will enact its initial business combination.

Horizon Aircraft Secures Investment from Canso Investment Counsel Ltd.

Retrieved on: 
Tuesday, December 5, 2023
Aircraft, Business analyst, Vertical, CAD, Combination, Growth, Aviation, History, Risk management

TORONTO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Robinson Aircraft Ltd., a hybrid electric Vertical TakeOff and Landing (“eVTOL”) aircraft developer (“Horizon Aircraft”), today announced a strategic investment in the form of a convertible note purchased by certain accounts of Canso Investment Counsel Ltd. (“Canso”) and affiliated companies for an aggregate $6.7 million CAD.

Key Points: 
  • TORONTO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Robinson Aircraft Ltd., a hybrid electric Vertical TakeOff and Landing (“eVTOL”) aircraft developer (“Horizon Aircraft”), today announced a strategic investment in the form of a convertible note purchased by certain accounts of Canso Investment Counsel Ltd. (“Canso”) and affiliated companies for an aggregate $6.7 million CAD.
  • Brandon Robinson, Chief Executive Officer and Co-Founder of Horizon Aircraft commented, “Canso has a strong history of supporting the growth of numerous businesses across Canada since its inception.
  • Canso is an experienced investor in aviation and space technology and is a champion of Canadian aerospace companies in particular.
  • Horizon Aircraft believes that Canso’s support with this financing will strengthen Horizon’s position as a leader in the eVTOL market and accelerate our developmental timeline.

Vision Sensing Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Initial Business Combination to January 3, 2024

Retrieved on: 
Monday, December 4, 2023
Acquisition, VSAC, Extension, Combination, Exercise

MIAMI, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”), a special purpose acquisition company, announced today that on November 30, 2023, its sponsor, Vision Sensing, LLC, deposited $60,000 into the Company’s trust account, which is the sum that the Company must pay to extend the date by which the Company must consummate its initial business combination from December 3, 2023, to January 3, 2024 (the “Extension”).

Key Points: 
  • MIAMI, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”), a special purpose acquisition company, announced today that on November 30, 2023, its sponsor, Vision Sensing, LLC, deposited $60,000 into the Company’s trust account, which is the sum that the Company must pay to extend the date by which the Company must consummate its initial business combination from December 3, 2023, to January 3, 2024 (the “Extension”).
  • The Company has issued to its sponsor a non-interest bearing, unsecured promissory note in the principal amount of $60,000 as consideration for the funding.
  • This is the second of up to six one-month extensions that the Company is authorized to obtain under its amended and restated certificate of incorporation as recently amended on October 25, 2023.
  • The combined company’s common stock is expected to trade on the Nasdaq Capital Market under the ticker symbol “NSIM”.

Weight Loss Treatment: SciSparc’s Obesity Drug Showed Positive Results in a Pre-Clinical Trial

Retrieved on: 
Friday, December 1, 2023
Hebrew University of Jerusalem, Blood, MEAI, Depression, TEL, Mouse, CWY, Combination, Animal, Appetite, Obesity, PEA, Central nervous system, Carbon, Safety, Therapy, Disorder, Pharmaceutical industry

TEL AVIV, Israel, Dec. 01, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced earlier this week successful results from a pre-clinical trial performed by Professor Joseph Tam from The Hebrew University of Jerusalem.

Key Points: 
  • The administered treatment exhibited a meaningful degree of tolerance, leaving the viability of the mice unaffected across all experimental groups.
  • A notable reduction in food consumption (appetite) and meal sizes was also observed, primarily at 40 and 20 mg/kg of MEAI.
  • "I am encouraged by the positive results from our recent pre-clinical trial, which represent another milestone in our ongoing efforts to develop safe and effective innovative therapies.
  • "The trial's findings, including increased metabolic activity, reduced appetite, and enhanced fat oxidation, are promising indicators of the treatment's efficacy and safety."

Vision Sensing Acquisition Corp. Announces Intention to Extend Period to Consummate Initial Business Combination to January 3, 2024

Retrieved on: 
Thursday, November 30, 2023
Transfer, Acquisition, VSAC, Extension, Combination, Exercise, Security (finance)

MIAMI, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose acquisition company, announced today that it has notified Continental Stock Transfer & Trust Company that it intends to extend the date by which the Company must consummate its initial business combination from December 3, 2023, to January 3, 2024, and that its sponsor, Vision Sensing, LLC, intends to deposit into the Company’s trust account an aggregate of $60,000 by December 4, 2023 (the “Extension”).

Key Points: 
  • MIAMI, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose acquisition company, announced today that it has notified Continental Stock Transfer & Trust Company that it intends to extend the date by which the Company must consummate its initial business combination from December 3, 2023, to January 3, 2024, and that its sponsor, Vision Sensing, LLC, intends to deposit into the Company’s trust account an aggregate of $60,000 by December 4, 2023 (the “Extension”).
  • In connection with the Extension, the Company intends to issue to its sponsor a non-interest bearing, unsecured promissory note in the principal amount of $60,000 as consideration for the funding.
  • This will be the second of up to six one-month extensions that the Company is authorized to obtain under its amended and restated certificate of incorporation as recently amended on October 25, 2023.
  • The combined company’s common stock is expected to trade on the Nasdaq Capital Market under the ticker symbol “NSIM”.

ClimateRock Announces Termination of Business Combination Agreement

Retrieved on: 
Thursday, November 30, 2023
Combination, Business analyst, Termination, CLRC

that the Company has elected to terminate the Amended and Restated Business Combination Agreement among the Company, E.E.W.

Key Points: 
  • that the Company has elected to terminate the Amended and Restated Business Combination Agreement among the Company, E.E.W.
  • and the other parties thereto, dated as of August 3, 2023 (the “Business Combination Agreement”), effective immediately, pursuant to Section 9.1(b) and 9.2 thereof, since the conditions to the closing of the initial business combination were not satisfied or waived by the outside date of September 30, 2023 (the “Termination”).
  • As a result, the Business Combination Agreement is of no further force and effect, except for certain specified provisions in the Business Combination Agreement, which shall survive the Termination and remain in full force and effect in accordance with their respective terms.
  • The Company and its sponsor intend to seek alternative ways to consummate an initial business combination.